Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

    Vous êtes ici :  
  1. Accueil
  2. Blog With Right Sidebar

Steroid asthma inhalers restrict children’s growth

Conclusion This systematic review has found that inhaled corticosteroid drugs suppress growth in children with persistent asthma who take them regularly, during the first year of treatment. This was high quality, well-conducted research, and its conclusions are likely to be reliable.  While the results are likely to worry parents, uncontrolled asthma can restrict a child’s activities and lower their quality of life. In severe cases, it can lead to life-threatening asthma attacks. Even low-grade, persistent symptoms can lead to fatigue, underperformance or absence from school as well as psychological problems, including stress, anxiety and depression. It's important that children continue to take their asthma medication as prescribed. Parents should discuss any concerns about their ...

Role of interventional pulmonology in the management of complicated parapneumonic pleural effusions and empyema

This article focuses on the role of the interventional pulmonologist in the diagnosis and management of pleural infection. In particular, we examine the role of pleural ultrasound in diagnostics, thoracocentesis and real‐time guided procedures, and the current management strategies, including the controversial role of medical thoracoscopy. (Source: Respirology)

A prospective 10-year follow-up polygraphic study of patients treated with a mandibular protruding device.

CONCLUSIONS: MPD treatment is well tolerated and effective in a long-term, 10-year perspective. Weight gain may jeopardize MPD effects. Both patients and relatives reported significantly less snoring and fewer periods of apnea. PMID: 25034825 [PubMed - as supplied by publisher] (Source: Sleep and Breathing)

Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma

Commentary on: Normansell R, Walker S, Milan SJ, et al.. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;1:CD003559. Context Asthma is a common chronic disease that affects over 300 million people worldwide. Between 5% and 10% of this population has severe asthma, which often remains uncontrolled despite maximal conventional treatment. Omalizumab is a recombinant humanised monoclonal antibody that binds circulating IgE antibody and decreases allergic, IgE-mediated airway inflammation.1 In the USA and many other countries, omalizumab is approved for the treatment of adults and adolescents aged 12 years and above with moderate-to-severe persistent allergic asthma, whose symptoms are poorly controlled with inhaled corticosteroids (ICS). European approval sti...

Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies

Conclusions: Evidence from observational studies shows that the combined treatment of LABAs and ICs is not associated with a higher risk of serious adverse events, compared to ICs alone. Major gaps identified were prospective design, paediatric population and inclusion of mortality as a primary outcome. (Source: Respiratory Research)

Search

Search